Document:

EX-10.13

 Exhibit 10.13 

EXTENSION AGREEMENT 
 This
Extension Agreement (the “Agreement”), effective this 1st day of November, 2014, is made by and between Nir Barzilai (the “Consultant”) and CohBar, Inc., a Delaware corporation (the “Company”). 

RECITALS 
 A. The
Consultant and the Company are parties to that Consulting Agreement dated November 1, 2011 (the “Original Agreement”), attached hereto as Exhibit A, which provides for its expiration twelve (12) months after its
effective date (the “Original Term”). 
 B. The Consultant and the Company have by words and actions indicated their mutual
consent to extend the Original Term of the Original Agreement and the Consultant’s provision of services to the Company under the Original Agreement have continued unabated since the effective date of the Original Agreement. 

C. The Consultant desires to continue providing, and the Company desires to continue receiving, the Consultant’s services as described in
the Original Agreement. 
 AGREEMENT 

It is therefore agreed as follows: 

1. The Consultant and the Company hereby confirm the extension of the Original Agreement from the Original Term through the date hereof. 

2. The Consultant and the Company hereby agree that the Original Agreement shall be further extended as of the date hereof for an additional
twelve (12) month period. As hereby extended, the Original Agreement shall remain in full force and effect in accordance with its terms. 
  

							
	NIR BARZILAI	 		 	COHBAR, INC.
				
	 /s/ Nir Barzilai
	 		 	By:	 	 /s/ Jon Stern

				
	Date:
    11/4/14                                    
	 		 	Name:	 	 Jon Stern

				
		 		 	Title:	 	 CEO

				
		 		 	Date:	 	 11/4/14

 CONSULTING AGREEMENT 

THIS CONSULTING AGREEMENT (the “Agreement”) is made as of the 1st day of November, 2011 (the “Effective Date”), by and
between Nir Barzilai, an individual residing at 233 Old Colony Rd., Hartsdale, NY 10530 (the “Consultant”) and COHBAR, INC., a corporation with its principal place of business at 910 Rockborn Street, Gaithersburg, MD 20878 (the
“Company”). In consideration of the promises contained herein and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: 

1. SERVICES. 
 (a) During
the Consulting Period (as hereinafter defined), the Company hereby engages the Consultant to provide, and the Consultant hereby agrees to provide, such consulting, advisory and related services to and for the Company as described on Exhibit A
hereto (the “Consulting Services”). The Consultant shall deliver the Consulting Services at the principal place of business of the Company or at such other location as the Consultant and the Company may mutually agree. The Consulting
Services shall be deemed to include any and all time spent by the Consultant traveling for the purpose of performing the Consulting Services. Notwithstanding the foregoing, this Agreement is subject to the Albert Einstein College of Medicine
Addendum to Consulting Agreement attached hereto as Exhibit B. 
 (b) The Consultant shall use her best efforts in the performance of
the Consulting Services and shall perform the Consulting Services diligently and conscientiously. The Company shall provide such access to its information, property and any other resources as may be required in order to permit the Consultant to
perform the Consulting Services. 
 2. TERM. The term of this Agreement shall commence on the Effective Date and shall continue for
twelve (12) months thereafter unless extended by the mutual consent of the parties or earlier terminated in accordance with Paragraph 4 hereof (the “Consulting Period”). 

(a) The Company shall pay the Consultant a fee of forty-two thousand dollars ($42,000) per year (the “Consulting Fee”) in
consideration of the Consultant’s performance of the Consulting Services. Such fee shall be paid at a rate of thirty five hundred dollars ($3500) per month during the period of the consulting agreement. 

(b) If requested by the Company, the Company agrees to reimburse the Consultant for reasonable disbursements made by the Consultant in
connection with the performance of the Consulting Services, including travel costs (Business Class if International) , telephone and telecopy/facsimile costs, duplicating fees, and delivery services (collectively, “Reimbursable Expenses”).

 (d) The Consultant shall provide the Company on a monthly basis with (i) an invoice for the Consulting Fee for the previous month;
and (ii) a listing of Reimbursable Expenses incurred by Consultant, an explanation of each Reimbursable Expense and an invoice for reimbursement of such Reimbursable Expenses for the previous month. The Company shall pay such Consulting Fee and
reimburse Consultant for such Reimbursable Expenses, as applicable, in immediately available funds, within thirty (30) days following receipt of such invoices by the Company. . 

4. TERMINATION; EFFECT OF TERMINATION OR EXPIRATION. 

(a) Consultant or Company may terminate this Agreement at any time upon thirty (30) days prior written notice. In the event of such
termination, the Consultant shall be entitled to receive (i) any Consulting Fee due but not yet paid as of the effective date of termination and (ii) reimbursement for any Reimbursable Expenses incurred by the Consultant prior to, but not
yet reimbursed as of, the effective date of termination. 

 (b) The provisions of Paragraphs 3, 4, 5, 6, 7, 9, 10 and 14 hereof shall survive the expiration
or termination of this Agreement. 
 5. CONFIDENTIALITY. It is anticipated that in the performance of the Consulting Services, the
Company shall provide to the Consultant or shall give the Consultant access to, certain information that the Company considers confidential or proprietary. The rights and obligations of the parties with respect to such confidential and proprietary
information are as follows: 
 (a) For purposes of this Agreement, “Confidential Information” is defined as any and all
information that is or has been disclosed by the Company to the Consultant, whether directly or indirectly, and whether in writing or orally, and that, by appropriate marking, is identified as confidential or proprietary at the time of its
disclosure. In the event that confidential information is provided visually or orally, obligations of confidence shall attach only to that information that is confirmed in writing within thirty (30) days of disclosure as being confidential or
proprietary. 
 (b) The Consultant shall hold in confidence and shall not disclose Confidential Information to any person. The Consultant
further agrees that she shall use Confidential Information only for the purpose for which it was disclosed and shall not use or exploit Confidential Information for her own benefit or the benefit of another without the prior written consent of the
Company. The Consultant shall disclose Confidential Information received under this Agreement only to persons who have a need to know such Confidential Information in the course of the performance of their duties and who are bound by written
agreement to protect the confidentiality of such Confidential Information. If the Consultant becomes aware of any disclosure not authorized hereunder, the Consultant shall notify the Company and take reasonable steps to prevent any further
disclosure or unauthorized use. 
 (c) At such time as the Company may request, the Consultant shall promptly deliver to the Company or
destroy all drawings, documents and other tangible manifestations of Confidential Information received by the Consultant pursuant to this Agreement, including all copies and reproductions thereof, with the exception of one copy of such material,
which may be retained by the Consultant for archival purposes. 
 (d) The Consultant agrees that the Company is and shall remain the
exclusive owner of all Confidential Information and all patent, copyright, trade secret, trademark and other intellectual property rights therein. No license or conveyance of such rights is granted or implied to the Consultant by or under this
Agreement. 
 (e) The Consultant shall not be required to treat any information as Confidential Information under this Agreement in the
event: (i) it is publicly available prior to the Effective Date or becomes publicly available thereafter through no wrongful act of the Consultant; (ii) it was known to the Consultant prior to the date of disclosure or becomes known to the
Consultant thereafter from a third party having an apparent bona fide right to disclose the information; (iii) it is disclosed by the Consultant in accordance with the terms of the Company’s prior written approval; (iv) it is
disclosed by the Company without restriction on further disclosure; (v) it is independently developed by the Consultant; or (vi) the Consultant is obligated to produce it pursuant to an order of a court of competent jurisdiction or a
facially valid administrative, Congressional or other subpoena, provided that the Consultant (A) promptly notifies the Company and (B) cooperates reasonably with the Company’s efforts to contest or limit the scope of such order. 

(f) The Consultant agrees that she shall not disclose any trade secrets or confidential or proprietary information of any other party to the
Company without such other party’s prior written consent. 
 6. INVENTIONS. All inventions, discoveries, data, technology,
designs, innovations and improvements (whether or not patentable or copyrightable) (collectively, “Inventions”) that are directly 

 
related to the business of the Company and that might be made by the Consultant in the performance of the Consulting Services shall be the sole property of the Company (“Company
Inventions”); provided, however, that in no event shall Company Inventions include any Invention of the Consultant that (a) was conceived, reduced to practice, published or submitted for publication, by the Consultant before
the commencement, or after the expiration, of the Consulting Period provided, that, if after the expiration, no Confidential Information was used; (b) was at any time conceived, reduced to practice, published or submitted for publication
independent of the performance of the Consulting Services; or (c) is subject to any obligation of the Consultant to assign such Invention to another party. At the Company’s request and expense, Consultant shall execute whatever documents
the Company and the Consultant deem reasonable to perfect ownership by the Company in any patents to the extent that such patents claim Company Inventions. The Consultant agrees to assign and hereby assigns to the Company all of the
Consultant’s right, title and interest in and to the Company Inventions and any and all related industrial and intellectual property rights (including moral rights in all Company Inventions) and applications therefore, in the United States and
elsewhere, and appoints any officer of the Company as her duly authorized attorney to execute, file, prosecute and protect the same before any government agency, court or authority. Not withstanding the foregoing, Consultant specifically maintains
ownership and authorship of training courses and other written products (such as “process” templates) developed for general use, developed outside or prior to this Agreement, or customized for use by the Company, but generally designed for
broad educational or other use by the Consultant. The Company agrees not to tape (audio or video) any programs delivered by the Consultant without prior agreement and purchase. 

7. PUBLICATION AND PUBLICITY. Except for disclosure by Consultant of the fact of her relationship with the Company to parties for whom
Consultant does, or desires to, provide professional services and except for disclosure by the Company to potential partners, investors or other parties with a legitimate business or regulatory interest in the Company, no party to this Agreement
shall use the name of any other party or of any staff member, employee or student of any other party or any adaptation, acronym or name by which any party is commonly known, in any advertising, promotional or sales literature or in any publication
without the prior written approval of the party or individual whose name is to be used. 
 8. OTHER ACTIVITIES OF CONSULTANT. The
Company hereby acknowledges and agrees that the Consultant may engage in providing professional services, that may or may not be similar to the Consulting Services, to other companies or organizations operating in the Company’s field. The
Company further acknowledges and agrees that nothing in this Agreement is intended to prevent Consultant from providing such professional services or to impose any covenants not to compete on Consultant. Notwithstanding the foregoing, Consultant
shall not consult for other companies on products that are directly competitive with Company’s products, without first obtaining the prior written approval of Company. 

9. INDEMNIFICATION. The Company agrees to indemnify, reimburse, and hold the Consultant harmless for, from and against all demands,
claims, actions or causes of action, assessments, losses, damages, liabilities, costs and expenses, including without limitation interest, penalties, attorneys’ fees, disbursements and expenses (collectively, “Damages”), asserted
against, imposed on, or incurred by the Consultant, directly or indirectly, arising in whole or in part out of or in connection with the performance of the Consulting Services including those by Company against Consultant. 

10. INDEPENDENT CONTRACTOR STATUS. The Consultant shall perform all services under this Agreement as an “independent
contractor” and not as an employee or agent of the Company. The Consultant is not authorized to assume or create any obligation or responsibility, express or implied, on behalf of, or in the name of, the Company or to bind the Company in any
manner. The Consultant shall be solely and unconditionally responsible for any and all city, state and federal income taxes, social security withholding taxes and any other self-employment tax obligation relating to any income that the Consultant
derives from this Agreement. The Company and the Consultant shall report payments made by the Company to the Consultant under this Agreement to the appropriate governmental agencies in a manner consistent with the Consultant’s status as an
independent contractor. 

 11. NOTICES. All notices required or permitted under this Agreement shall be in writing
and shall be deemed effective upon personal delivery or upon deposit in the United States Post Office, by registered or certified mail, postage prepaid, addressed to the other party at the address shown above, or at such other address or addresses
as either party shall designate to the other in accordance with this Paragraph 12. 
 12. ENTIRE AGREEMENT. This Agreement
constitutes the entire agreement between the parties with respect to, and supersedes all prior agreements and understandings, whether written or oral, relating to the subject matter of this Agreement. This Agreement may not be modified except by a
writing signed by each of the parties. 
 13. GOVERNING LAW. This Agreement shall be construed, interpreted and enforced in
accordance with the laws of the State of New York, without giving effect to conflict of laws provisions. 
 14. SUCCESSORS AND
ASSIGNS. This Agreement shall be binding upon, and inure to the benefit of, both parties and their respective successors and assigns, including any corporation with which, or into which, the Company may be merged or that may succeed to any of
its assets or business; provided, however, that the obligations of the Consultant are personal and shall not be assigned by her. 

15. SEPARABILITY. If any provision of this Agreement is found to be unenforceable, the remainder shall be enforced as fully as possible
and the unenforceable provision shall be deemed modified to the limited extent required to permit its enforcement in a manner most closely approximating the intention of the parties as expressed herein. 

16. WAIVER. No failure or delay by either party hereto in exercising any right, power or privilege hereunder shall operate as a waiver
thereof, nor shall any single or partial exercise thereof preclude any other or future exercise of any right, power or privilege. 
 IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year set forth above. 
  

			
	COMPANY
		
	By:	 	         /s/ Mark A. Rampy

		 	Name: Mark A. Rampy
		 	Title:CEO
	
	CONSULTANT
	
	 /s/ Nir Barzilai

 EXHIBIT A 

CONSULTING SERVICES 
 In the scope of this
contract, the Consultant is likely to perform consulting including, but not limited to, the following services: 
  

	1.	General Business Services 

 EXHIBIT B 

ALBERT EINSTEIN COLLEGE OF MEDICINE ADDENDUM TO CONSULTING AGREEMENT 

 ALBERT EINSTEIN COLLEGE OF MEDICINE ADDENDUM TO CONSULTING AGREEMENT 

Addendum to Consulting Agreement between             Nir
Barzilai             (Consultant) and             CohBar, Inc.
            (Company) dated             November 1,
2011            (Agreement). 
 1. The purpose of this Addendum is to ensure
that Consultant’s commitments to Company are consistent with Consultant’s obligations to the Albert Einstein College of Medicine of Yeshiva University (“EINSTEIN”). Thus, the undersigned agree that this Addendum is a part of the
Agreement and further agree that if anything in the Agreement is inconsistent with this Addendum, this Addendum shall govern. 
 2. The
Company acknowledges that the terms and conditions of the Agreement are subordinate to obligations which Consultant has to EINSTEIN as an EINSTEIN faculty member and employee, and in the event that there is any conflict or inconsistency between
terms of the Agreement and the Consultant’s obligations to EINSTEIN, the obligations to EINSTEIN will govern. 
 3. The Company may not
use the name of Yeshiva University or the Albert Einstein College of Medicine or any variation or adaptation thereof without the prior written approval of EINSTEIN. 

4. The Company agrees and understands that Consultant has a pre-existing obligation to assign to EINSTEIN all of Consultant’s rights in
intellectual property conceived or made by Consultant as a result of research that has been or is supported entirely or partly by EINSTEIN resources. Company has no rights by reason of this Agreement in any intellectual property that is subject to
Consultant’s obligations to EINSTEIN. 
 5. Each party to the Agreement acknowledges (i) that the Consultant is entering into the
Agreement, and providing services to the Company, in the Consultant’s individual capacity and not as an employee or agent of EINSTEIN, (ii) EINSTEIN is not a party to the Agreement and has no liability or obligation hereunder, and
(iii) EINSTEIN is intended as a third party beneficiary of this Addendum and certain provisions of this Addendum are for the benefit of EINSTEIN and are enforceable by EINSTEIN in its own name. 

6. The above provisions shall be and hereby are in force and effect for the entire term of any Agreement between Consultant and Company. 

 

					
	ACCEPTED:	  		  	
			
	     /s/ Mark A.
Rampy.            
	  		  	        11/1/11                    
	Authorized Officer of Company	  		  	Date
			
	     /s/ Nir
Barzilai            
	  		  	        11/11/11                    
	Consultant	  		  	DateEX-10.14

 Exhibit 10.14 

CONSULTING AGREEMENT 
 THIS CONSULTING
AGREEMENT (the “Agreement”) is made as of the 29th day of September, 2014 (the “Effective Date”), by and between Dr. Pinchas Cohen, an individual residing at
16577 Chattanooga Place, Pacific Palisades, CA 90272 (the “Consultant”), and COHBAR, INC., a Delaware corporation with its principal place of business at 2265 East Foothill Blvd., Pasadena, CA 91107 (the “Company”).
In consideration of the promises contained herein and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: 

1. SERVICES. 
 (a) During the Consulting
Period (as hereinafter defined), the Company hereby engages the Consultant to provide, and the Consultant hereby agrees to provide, such consulting, advisory and related services to and for the Company as described on Exhibit A hereto (the
“Consulting Services”). The Consultant shall deliver the Consulting Services at the principal place of business of the Company or at such other location as the Consultant and the Company may mutually agree. The Consulting Services
shall be deemed to include any and all time spent by the Consultant traveling for the purpose of performing the Consulting Services. Notwithstanding the foregoing, this Agreement is subject to the University of Southern California Davis School of
Gerontology (“University”) Addendum to Consulting Agreement attached hereto as Exhibit B. 
 (b) The Consultant
shall use his best efforts in the performance of the Consulting Services and shall perform the Consulting Services diligently and conscientiously. The Company shall provide such access to its information, property and any other resources as may be
required in order to permit the Consultant to perform the Consulting Services. 
 2. TERM. The term of this Agreement shall commence on the Effective
Date and shall continue for twelve (12) months thereafter unless extended by the mutual written agreement of the parties or earlier terminated in accordance with Section 4 hereof (the “Consulting Period”). 

 

	3.	COMPENSATION. 

 (a) The Company shall pay the Consultant a consulting fee (the
“Consulting Fee”) as provided in Exhibit A in consideration of the Consultant’s performance of the Consulting Services in accordance with the terms of this Agreement. 

(b) If requested by the Company, the Company agrees to reimburse the Consultant for reasonable disbursements made by the Consultant in
connection with the performance of the Consulting Services, including travel costs (Business Class if International), telephone and telecopy/facsimile costs, duplicating fees, and delivery services (collectively, “Reimbursable
Expenses”). 
 (c) The Consultant shall provide the Company on a monthly basis with (i) an invoice for the Consulting Fee for
the previous month, describing the services delivered during the prior month; and (ii) a listing of Reimbursable Expenses incurred by Consultant and an invoice for reimbursement of such Reimbursable Expenses for the previous month. The Company
shall pay such Consulting Fee and reimburse Consultant for such Reimbursable Expenses, as applicable within thirty (30) days following receipt of such invoices by the Company. 

  
 (1) 

 4. TERMINATION; EFFECT OF TERMINATION OR EXPIRATION. 

(a) Consultant or Company may terminate this Agreement at any time upon thirty (30) days prior written notice. In the event of such
termination, the Consultant shall be entitled to receive (i) any Consulting Fee due but not yet paid as of the effective date of termination and (ii) reimbursement for any Reimbursable Expenses incurred by the Consultant prior to, but not
yet reimbursed as of, the effective date of termination. 
 (b) Upon termination or at any other time upon the request of the Company, the
Consultant shall promptly deliver to the Company all drawings, documents and other tangible manifestations of the Consulting Services and any Confidential Information received by the Consultant pursuant to this Agreement, including all copies and
reproductions thereof, with the exception of one copy of such material, which may be retained by the Consultant for archival purposes. 

(c) The provisions of Sections 4 through 17 hereof shall survive the expiration or termination of this Agreement. 

5. CONFIDENTIALITY. It is anticipated that in the performance of the Consulting Services, the Company shall provide to the Consultant or shall give the
Consultant access to, certain information that the Company considers confidential or proprietary. The rights and obligations of the parties with respect to such confidential and proprietary information are as follows: 

(a) For purposes of this Agreement, “Confidential Information” is defined as any and all information that is or has been
disclosed by the Company to the Consultant (including any disclosed prior to the Effective Date), whether directly or indirectly, and whether in writing or orally, and that, by appropriate marking, is identified as confidential or proprietary at the
time of its disclosure. In the event that confidential information is provided visually or orally, obligations of confidence shall attach only to that information that is confirmed in writing within thirty (30) days of disclosure as being
confidential or proprietary. 
 (b) The Consultant shall hold in confidence and shall not disclose Confidential Information to any person.
The Consultant further agrees that he shall use Confidential Information only for the purpose for which it was disclosed and shall not use or exploit Confidential Information for his own benefit or the benefit of another without the prior written
consent of the Company. The Consultant shall disclose Confidential Information received under this Agreement only to persons who have a need to know such Confidential Information in the course of the performance of their duties and who are bound by
written agreement to protect the confidentiality of such Confidential Information. If the Consultant becomes aware of any disclosure not authorized hereunder, the Consultant shall notify the Company and take reasonable steps to prevent any further
disclosure or unauthorized use. 
 (c) The Consultant agrees that the Company is and shall remain the exclusive owner of all Confidential
Information and all patent, copyright, trade secret, trademark and other intellectual property rights therein. No license or conveyance of such rights is granted or implied to the Consultant by or under this Agreement. 

 (d) Except as otherwise provided herein, under any other written agreement between Consultant and
Company, or under applicable law Consultant shall not be required to treat any information as Confidential Information under this Agreement that: (i) was publicly available prior to the Effective Date or becomes publicly available thereafter
through no wrongful act of the Consultant; (ii) was known to the Consultant prior to the date of disclosure and Consultant’s use or disclosure of such information would not violate any rights of the Company or any third party or cause the
Company to breach any obligation to any third party; (iii) is disclosed to the Consultant after the Effective Date by a third party having an apparent bona fide right to disclose the information; (iv) the Company gives the Consultant
written approval to use or disclose, provided such use complies with the Company’s written instructions; (iv) is disclosed by the Company without restriction on further disclosure; (vi) is independently developed by the Consultant
without use of or reference to the Confidential Information; or (vi) the Consultant is obligated to produce it pursuant to an order of a court of competent jurisdiction or a facially valid administrative, Congressional or other subpoena,
provided that the Consultant (A) promptly notifies the Company (B) cooperates reasonably with the Company’s efforts to contest or limit the scope of such order and (C) if required to make such disclosure, discloses only that part
of the information that is requested and required by law to be disclosed. Nothing in this Section shall be interpreted or construed to grant Consultant any right to make use of or disclose information in violation of applicable law or the
Company’s copyright, patent, or other Company intellectual property rights. 
 (e) The Consultant agrees that he shall not disclose to
the Company or make any use of any trade secrets or confidential or proprietary information or those of any other party in performing the Consulting Services, without Company’s and such other party’s prior written consent. 

6. INVENTIONS. 
 (a) All inventions,
discoveries, data, technology, designs, innovations and improvements (whether or not patentable or copyrightable) (collectively, “Inventions”) that directly relate to the business or research and development of the Company and that
might be conceived, reduced to practice, or made by the Consultant alone or in combination with others in the performance of the Consulting Services or with the use of any Confidential Information or other property of the Company, shall be the sole
property of the Company (“Company Inventions”); provided, however, that in no event shall Company Inventions include any Excluded Inventions (as defined below) or any Invention of the Consultant that (a) was
conceived, reduced to practice, published or submitted for publication, by the Consultant before the commencement, or after the expiration, of the Consulting Period provided such Invention did not make use of any Confidential Information or other
property of the Company; (b) was at any time conceived, reduced to practice, published or submitted for publication independent of the performance of the Consulting Services; or (c) is subject to any obligation of the Consultant to assign
such Invention to another party. At the Company’s request and expense, Consultant shall execute whatever documents the Company shall deem reasonable to perfect ownership by the Company in any patents to the extent that such patents claim
Company Inventions. The Consultant agrees to assign and hereby assigns to the Company all of the Consultant’s right, title 

 
and interest in and to the Company Inventions and intellectual property rights and applications therefore, in the United States and elsewhere, and appoints any officer of the Company as his duly
authorized attorney to execute, file, prosecute and protect the same before any government agency, court or authority. 
 (b) To prevent
untimely or wrongful disclosure or exploitation of the Company Inventions the Consultant shall provide the Company with reasonable prior notice and a copy of (i) any proposed patent or other intellectual property application that claims
technology owned by the Company and (ii) any proposed publication or manuscript disclosing previously unpublished Inventions owned by the Company. 

7. PUBLICATION AND PUBLICITY. Except for disclosure by Consultant of the fact of his relationship with the Company to parties for whom Consultant does,
or desires to, provide professional services the Consultant shall not use the name of the Company or of any staff member or employee or any adaptation, acronym or name by which the Company is commonly known, in any advertising, promotional or sales
literature or in any publication without the prior written approval of the Company. 
 8. OTHER ACTIVITIES OF CONSULTANT. 

(a) The Company hereby acknowledges and agrees that the Consultant may engage in providing professional services, which may or may not be
similar to the Consulting Services, to other companies or organizations operating in the Company’s field. The Company further acknowledges and agrees that nothing in this Agreement is intended to prevent Consultant from providing such
professional services or to impose any covenants not to compete on Consultant. 
 9. COMPLIANCE WITH UNIVERSITY POLICIES. The Company agrees and
understands that Consultant is an employee of the University. In connection with such employment, Consultant has entered into certain agreements with the University relating to ownership of intellectual property rights, conflicts of interest and
other matters, and is subject to certain policy statements of the University (collectively, the “University Agreement”). The Consultant represents and warrants that he has and will obtain all approvals and consents, if any, from the
University necessary for the Consultant to perform the Consulting Services for the Company under this Agreement and that his performance of the Consulting Services shall not, in any way, violate the University Agreement. The Consultant understands
that he is solely responsible and assumes all risk for compliance with the terms of the University Agreement. If any provision of this Agreement is hereinafter determined to be in conflict with the University Agreement, Consultant agrees to
immediately notify the Company of the conflict. 
 10. INDEPENDENT CONTRACTOR STATUS. The Consultant shall perform all services under this Agreement
as an “independent contractor” and not as an employee or agent of the Company. The Consultant is not authorized to assume or create any obligation or responsibility, express or implied, on behalf of, or in the name of, the Company or to
bind the Company in any manner. The Consultant shall be solely and unconditionally responsible for any and all city, state and federal income taxes, social security withholding taxes and any other self-employment tax obligation relating to any
income that the Consultant derives from this Agreement. The 

 
Company and the Consultant shall report payments made by the Company to the Consultant under this Agreement to the appropriate governmental agencies in a manner consistent with the
Consultant’s status as an independent contractor. 
 11. NOTICES. All notices required or permitted under this Agreement shall be in writing and
shall be deemed effective upon personal delivery or upon deposit in the United States Post Office, by registered or certified mail, postage prepaid, addressed to the other party at the address shown above, or at such other address or addresses as
either party shall designate to the other in accordance with this Section 11. 
 12. ENTIRE AGREEMENT. This Agreement constitutes the
entire agreement between the parties with respect to, and supersedes all prior agreements and understandings, whether written or oral, relating to the Consultant’s engagement by the Company after the Effective Date. This Agreement does not
modify, amend or change any obligations the Consultant may have to the Company or the Company’s rights under any agreement relating to intellectual property created by the Consultant and licensed or assigned to the Company prior to the
Effective Date. This Agreement may not be modified except by a writing signed by each of the parties. 
 13. GOVERNING LAW. This Agreement shall be
construed, interpreted and enforced in accordance with the laws of the State of California, without giving effect to conflict of laws provisions. 
 14.
SUCCESSORS AND ASSIGNS. This Agreement shall be binding upon, and inure to the benefit of, both parties and their respective successors and assigns, including any corporation with which, or into which, the Company may be merged or that may
succeed to any of its assets or business; provided, however, that the obligations of the Consultant are personal and shall not be assigned by him. 

15. SEPARABILITY. If any provision of this Agreement is found to be unenforceable, the remainder shall be enforced as fully as possible and the
unenforceable provision shall be deemed modified to the limited extent required to permit its enforcement in a manner most closely approximating the intention of the parties as expressed herein. 

16. WAIVER. No failure or delay by either party hereto in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor
shall any single or partial exercise thereof preclude any other or future exercise of any right, power or privilege. 
 17. LIMITATION OF DAMAGES. In
no event shall either party be liable to the other for any incidental, special, indirect, punitive or consequential damages arising out of or relating to this Agreement, even if such party or any of its authorized representatives has been advised of
the possibility of such damages. Either party’s cumulative liability to the other party on any ground pursuant to this Agreement shall not exceed the annual sum equal to the fees paid or due payable to the other party hereunder. 

[Signature Page Follows] 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year set forth above. 

COMPANY 
  

					
	By:	 	 /s/ Jon Stern
                September 29, 2014

		 	Name: Jon Stern
		 	Chief Executive Officer
	
	CONSULTANT
	
	 /s/ Pinchas Cohen
            September 28, 2014

	Pinchas Cohen

 EXHIBIT A 

Consulting Fee and Services 
 CONSULTING FEE 

$42,000 annually, payable at a rate of $3,500 per month. 

CONSULTING SERVICES 
 In the scope of this contract, the
Consultant is likely to perform consulting including, but not limited to, the following services: 
  

	1.	General business services 

  

	2.	Scientific and medical and research advisory services 

 EXHIBIT B 

USC Davis School of Gerontology Addendum to Consulting Agreement 

 University of Southern California 

Relationships with Industry 
 1. Purpose 

The purpose of this policy is to: 
  

	 	•	 	Support USC’s standard of maintaining a culture of ethics in its business relations and to minimize conflicts of interest and the appearance of impropriety in our relationships with pharmaceutical companies,
biotechnology companies, device and medical equipment manufacturers and other healthcare suppliers (“Industry”). 

  

	 	•	 	Provide guidelines for USC Healthcare Professionals (defined below) for their interactions with Industry. 

  

	 	•	 	Assist USC Healthcare Professionals in exercising independent clinical judgment at all times that is free from influence by relationships with Industry. 

 

	 	•	 	Assist USC Healthcare Professionals in complying with federal, state and local laws and regulations, including the federal Anti-Kickback laws. 

2. Background 
 USC recognizes that Industry possesses
knowledge about the safety and efficacy of pharmaceuticals, medical devices, and medical supplies that may be of value to USC Healthcare Professionals and that may benefit their patients. In addition, USC Healthcare Professionals may have expertise
that is beneficial to Industry. 
 However, in certain circumstances these relationships can improperly influence, or appear to improperly influence,
clinical, purchasing or prescribing decisions. In addition, it is a violation of the federal Anti-Kickback laws to knowingly receive anything of value that induces a clinician to use or purchase products/services (e.g., prescription drugs or medical
devices) that are paid for by government programs, such as Medicare or Medicaid. (See Exhibit A, a summary of applicable laws and standards, below.) 

Fundamentally, interactions with Industry must serve legitimate educational, research and clinical purposes, and contribute to better health care for
patients. This policy establishes standards for appropriate interactions with Industry. In addition to the standards established in this policy, it is important for all USC Healthcare Professionals to comply with the university’s Conflict of
Interest in Professional and Business Practices policy. 
 3. Scope 

This policy applies to all “USC Healthcare Professionals”, who are defined as: 

 

	 	•	 	University faculty members (including part-time and visiting faculty), students, staff, and other employees (including residents and fellows), who interact with Industry and who have influence directly or indirectly
over the prescribing, dispensing or purchasing of Industry products or services; and 

  

	 	•	 	The USC affiliated faculty practice plan corporations and units listed in Exhibit B; and 

  

	 	•	 	USC University Hospital and Norris Cancer Hospital. 

 The policy applies to on-site and off-site interactions
with Industry. 

  
 1 

 4. Types of Interactions Covered by this Policy 

This policy provides guidelines for the following types of interactions with Industry: 

 

	 	•	 	Consulting Arrangements and Industry-sponsored Speaking Engagements 

  

	 	•	 	Gifts, Invitations and Free Meals 

  

	 	•	 	Attendance at Industry-sponsored Conferences 

  

	 	•	 	Education Grants and Trainee Scholarships 

  

	 	•	 	Unrestricted Grants 

  

	 	•	 	Industry-sponsored Research Projects 

  

	 	•	 	Training and Education Regarding Use of Medical Devices 

  

	 	•	 	Pharmaceutical Samples, Discounts and Other Reductions in Price 

  

	 	•	 	Site Access by Industry Representatives 

  

	 	•	 	Ghostwriting 

  

	 	•	 	Recusal from Purchasing Decisions 

 A. Consulting Arrangements and Industry-sponsored Speaking Engagements

 This section covers all consulting arrangements with Industry, including participating on advisory committees, giving lectures or other presentations,
Industry-sponsored speaking engagements, providing training and advice or other services for payment (collectively, “Consulting Arrangements”). Special considerations for Industry-sponsored speaking engagements (e.g., speakers’
bureaus or promotional presentations) are discussed in Section A.3 below. 
 A.1 Requirements for Consulting Arrangements 

A.1.1 USC Healthcare Professionals are ultimately responsible to ensure that all Consulting Arrangements: 

 

	 	•	 	Are in writing; and 

  

	 	•	 	Describe in reasonable detail the services provided by USC Healthcare Professionals; and 

  

	 	•	 	Provide no more than fair-market compensation; and 

  

	 	•	 	Require necessary and legitimate services that are actually rendered; and 

  

	 	•	 	Are not entered into for longer than a one year term and with extensions being treated as new agreements requiring compliance with all sections of Section A; and 

 

	 	•	 	Are not motivated (or appear to be motivated) by any improper purpose, such as to incentivize the USC Healthcare Professional to change or maintain his or her purchasing or prescribing habits; and 

 

	 	•	 	Are not provided at a time when the USC Healthcare Professional is otherwise engaged in University activities, such as the provision of healthcare; and 

 

	 	•	 	Comply with the USC Faculty Handbook on Outside Consulting and the USC Conflicts of Interest in Ethics Policy and Procedure; and 

  

	 	•	 	Are submitted in advance for review and approval prior to agreeing to, engaging in, or accepting reimbursement for the consulting activities; and 

 

	 	•	 	If the consulting arrangement is related in any way to a company where the USC Healthcare Professional is also involved in a sponsored research project, the 

 

	 	•	 	USC Healthcare Professional has completed and submitted a Statement of Outside Interests under USC’s Conflict of Interest in Research Policy. 

A.1.2 In addition, before signing a Consulting Arrangement, USC Healthcare Professionals should consider whether the request for services has originated
from an appropriate unit/division within Industry. For example, Industry marketing representatives generally are not the appropriate unit to engage services that are solely scientific in nature. 

  
 2 

 A.1.3 USC Healthcare Professionals may accept meals, travel and lodging in connection with meetings for
consulting services, so long as they are of “modest value” and incidental to the consulting or other services provided. See Exhibit C for guidelines on establishing “Modest Value.” 

A.2 Disclosure and Approval of Consulting Arrangements 

A.2.1 All Consulting Arrangements must be disclosed to, reviewed and approved by the USC Healthcare Professional’s Department Chair or Chair
Designee (the “USC Approver”) before consulting services can be rendered (in the event that the Department Chair or Chair Designee has a conflict of interest, the Chair shall forward the agreement to the Dean or Dean’s Designee for
approval. In the event that the Dean has a conflict of interest, the Dean shall forward the agreement to the Provost or the Provost’s Designee for approval). Consulting Arrangements may also require approval of the Dean or his/her designee, as
determined at the Dean’s discretion. The USC Approver/s is/are responsible for the following: 
  

	 	•	 	To ensure that the services provided under the Consulting Arrangement comply with this policy and do not constitute a conflict of interest or commitment as described in USC’s Conflict of Interest and Ethics Policy;

  

	 	•	 	To confirm that the USC Healthcare Professional has submitted a Statement of Outside Interests if the Consulting Arrangement relates in any way to a sponsored research project; 

 

	 	•	 	To maintain a copy of the Consulting Arrangement in accordance with the university’s record retention policy and a copy of their written review which has been signed by the Chair; and 

 

	 	•	 	To report annually in writing to his/her Dean, upon the Dean’s request, all Consulting Arrangements that have been disclosed, an update of ongoing Consulting Arrangements and the outcome of the Chair’s review.

 A.2.2 USC Healthcare Professionals must disclose to their students, residents and fellows any Consulting Arrangement they may have
or have had that relates to Industry products (e.g., device, product, equipment) that are being described, taught or used in an educational or instructional setting (e.g., classroom, operating room, lab). 

A.3 Industry-sponsored Speaking Engagements/Lectures 

A.3.1 USC Healthcare Professionals may participate as bona fide lecturers at an Industry-sponsored conference if they: 

 

	 	•	 	Comply with the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Commercial Support, the Accreditation Council for Pharmacy Education (ACPE) or the American Dental Association (ADA),
as appropriate, whether or not CE credit is awarded; and 

  

	 	•	 	Ensure to the extent possible that the information they present is based on the best scientific evidence available; and 

  

	 	•	 	Disclose to attendees orally and/or in writing, their financial relationship with Industry and that their opinions are their own and not intended to represent USC; and 

 

	 	•	 	Ensure that the requirements set forth in A.1 and A.2 are satisfied. 

 A.3.2 USC Healthcare
Professionals are strongly discouraged from speaking as a paid promotional speaker at Industry-sponsored events, i.e. speaker’s bureaus. To the extent a USC Healthcare Professional chooses to engage as a speaker at such Industry-sponsored
events, he/she must: 
  

	 	•	 	Have control of the content (meaning that a speaker directly determines and has ultimate responsibility for the substance and content of the presentation – the speaker must always cite the source of the slide if
not developed by the speaker); and 

  

	 	•	 	Ensure to the extent possible that the information presented is based on the best scientific evidence available; and 

  

	 	•	 	Not present unsolicited off-label uses of FDA-approved drugs or devices; and 

  

	 	•	 	Disclose to attendees orally and/or in writing, their financial relationship with Industry and also that their opinions are their own and not intended to represent USC; and 

  
 3 

	 	•	 	Ensure that the requirements set forth in A.1 and A.2 are satisfied. 

 B. Gifts, Invitations and Free Meals

 B.1 
 USC Healthcare Professionals may not accept
gifts of any kind from Industry, including food, branded items such as pens and notepads, even if such gifts are of nominal value. Existing branded items may not be utilized in patient- care areas and must be removed. 

B.2 
 USC Healthcare Professionals may not accept any item
from an Industry representative that is for the Healthcare Professional’s or family member’s personal benefit, such as floral arrangements, artwork, golf balls, sporting bags, or tickets to sporting, musical or other types of entertainment
events. 
 B.3 
 USC Healthcare Professionals and/or
their family members may not accept Industry invitations for free or discounted admission to entertainment events such as plays, sporting events or golf outings, even where some business may be discussed. 

B.4 
 With the exception of food provided in accordance
with CE accredited programs, or meals provided in accordance with Section C of this policy, USC Healthcare Professionals may not accept any food or meals from Industry representatives. For example: 

 

	 	•	 	USC Healthcare Professionals may not accept meals on or off campus that do not meet the criteria set forth in Section C below. 

  

	 	•	 	Industry may not provide/deliver to educational/instructional settings, meals for students, residents or fellows. 

  

	 	•	 	Industry may not provide/deliver any meals in patient care areas (e.g., clinics, hospitals). 

 B.5 

USC Healthcare Professionals may not accept payment or any other remuneration from Industry in exchange for attending any lunch, dinner or reception. 

B.6 
 USC Healthcare Professionals may not accept Industry
donations/loans of equipment, devices or supplies, except as follows: 
  

	 	•	 	Research: Industry may provide equipment for use in research related activities conducted on behalf of the manufacturer. 

  

	 	•	 	Evaluation: Industry may provide demonstration or evaluation products without charge, to allow the USC Healthcare Professional to assess the appropriate use and functionality of the product and to determine whether and
when to use, order, purchase or recommend the product in the future. 

  

	 	•	 	Early Adopter Feedback: Industry may provide new technologies without charge to promote education and clinical care in an effort to solicit early adopter feedback on the new technology. 

  
 4 

	 	•	 	Bona fide Discount: Industry may provide free or discounted equipment, devices or supplies in connection with the purchase of other items as part of a bona fide discount that complies with the Discount Safe Harbor to
the federal Anti-Kickback laws. 

 These arrangements: 
  

	 	•	 	Must comply with Sections A, F and H.3 of this policy, as appropriate; and 

  

	 	•	 	Must be managed centrally by the appropriate School (ex. Keck, Dentistry, Pharmacy); and 

  

	 	•	 	Unless otherwise approved by the Office of Compliance, provide for the title of the equipment to be retained by the manufacturer; and 

 

	 	•	 	Be documented in writing and submitted to the Office of Compliance for prior review and approval; and 

  

	 	•	 	Most importantly, will never be taken into account in awarding contracts or in making purchasing or prescribing decisions. 

C. Attendance at Industry-sponsored Conferences 
 C.1

 USC Healthcare Professionals may attend Industry-sponsored educational meetings, lectures and conferences containing objective scientific and
educational information that promotes evidence-based medicine and scientific research and where support of industry is prominently disclosed. (USC Healthcare Professionals are attending conferences as attendees, and not faculty/lecturers, if they
only present a peer-reviewed poster or paper.) USC Healthcare Professionals shall follow these standards when attending Industry-sponsored educational meetings: 
  

	 	•	 	Educational programs sponsored by Industry must be structured so as not to improperly influence purchasing or prescribing decisions. 

 

	 	•	 	USC Healthcare Professionals’ main incentive in attending the Industry-sponsored educational meetings should be to further their knowledge on the subject(s) presented. USC Healthcare Professionals should ensure
that such meetings are inclusive of and led by those within Industry who are qualified to present a program that is aimed at promoting evidenced-based medicine and scientific research. Meetings led by marketing representatives in lieu of
Industry’s scientific team would not qualify as a legitimate educational meeting. 

  

	 	•	 	USC Healthcare Professionals may not accept any reimbursement from Industry for meeting registration fees, transportation, lodging, or incidentals to defray the costs of attending the conference. 

C.2 
 USC Healthcare Professionals may attend modest
receptions and meals provided by Industry in connection with educational meetings/conferences. The meals and receptions should be incidental and subordinate to the educational content of the meetings. The meal or reception should be modest in value
and conducive to discussion among those participating in the event. 
 C.3 

USC Healthcare Professionals may not “dine and dash” (i.e., take food provided by Industry without actually participating in the educational lecture
or accept an Industry representative’s offer to provide a meal without providing educational content). 
 C.4 

A USC Healthcare Professional shall not under any circumstances accept reimbursement for transportation, lodging, meals or incidentals for the cost of his or
her spouse or other guest(s). 

  
 5 

 D. Education Grants and Trainee Scholarships 

D.1 Education Grants 
 Education grants may provide funding
for valuable activities that are important to the University’s mission. These activities include but are not limited to sponsorship of grand rounds, journal club or morbidity and mortality conferences, all of which are conducted to further
education. USC Healthcare Professionals shall comply with the following guidelines when accepting education grants from Industry: 
  

	 	•	 	All education grants received from Industry must be clearly documented in a written agreement signed by the authorized signers for Industry and USC (USC-affiliated faculty practice plan corporations as noted in Exhibit
B are not authorized to execute agreements for education grants). 

  

	 	•	 	USC Healthcare Professionals may only consider education grants from Industry for projects that directly benefit USC patients or that advance health policy or education. Research grants are separately addressed in
Section F “Industry-sponsored Research Projects.” 

  

	 	•	 	Education events conducted by USC or a USC Healthcare Professional using grant funds from Industry must comply with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support,
Accreditation Council for Pharmacy Education (ACPE), or the American Dental Association (ADA), as appropriate, regardless of whether continuing-education credit is awarded or available for the event. 

 

	 	•	 	Educational grants for “bona fide fellowship” training* may not exceed the actual direct costs of the fellowship program. Where the services of the fellow will generate clinical income to the department, the
costs of the program must be offset by such income in determining the allowable funding. 

  

	 	•	 	In general, USC Healthcare Professionals should not accept funding for education that originates from Industry’s sales and marketing departments or that is offered in connection with the purchase or sale of goods
or services. The USC Office of Compliance should be contacted before a USC Healthcare Professional accepts funding for educational or other purposes that originates from Industry’s marketing and/or sales departments. 

 

	 	•	 	No funds will be accepted or used for the personal benefit of individual Healthcare Professionals. All donated funds provided by Industry for education will be applied toward the applicable educational or other
earmarked project. Donated funds must be deposited into a USC restricted account in accordance with USC policies and Industry requirements for the receipt, management and dispensing of grant monies. It is not acceptable to deposit these funds into
Practice Plan or HRA accounts. Funds from other sources for other purposes will not be commingled with these grant monies. 

  

	 	•	 	USC Healthcare Professionals will not accept funds from Industry for any project if Industry requires as a condition of the donation that it approve or influence the materials developed with such funds. This is to avoid
any opportunity for Industry to transform a project into a marketing program for Industry’s benefit. 

  

	 	•	 	Education grant programs associated with a specific USC Healthcare Professional will be deposited into an appropriate University account as described above. To the extent possible, the funds will be administered in such
a manner that the USC Healthcare Professional will not know the identity of donors or the amounts donated by Industry. 

  

	 	•	 	Sponsorships and donations by Industry will never be taken into account in awarding contracts or in making purchasing or prescribing decisions. 

* A bona fide fellowship is one that is ABMS accredited, if accreditation is available for the subspecialty training in question. Where such accreditation is
not available (i.e. the subspecialty is not recognized by ABMS for certification purposes), the fellowship must be a formal subspecialty program with clearly identified didactic and clinical requirements where the training elements predominate over
patient care as the focus of the program. 
 D.2 Trainee Scholarships to Conferences 

USC recognizes that attendance at educational conferences may further the knowledge of the attendees and benefit USC patients. However, receipt of such funding
directly by Trainees from Industry could inappropriately influence medical or other clinical students, residents, fellows and other healthcare professionals in training (“Trainees”), or 

  
 6 

 
create the appearance of impropriety. To ensure that Trainees are not inappropriately influenced by Industry, the following guidelines shall apply to Industry funding of Trainee scholarships to
educational conferences: 
  

	 	•	 	Donated funds supporting Trainee scholarships must be managed as described in section D.1. 

  

	 	•	 	The USC Healthcare Professional(s) must select the particular Trainees who will receive the Industry- donated funds with no input from the Industry. 

 

	 	•	 	Trainees may not receive funds or be reimbursed for expenses directly by Industry for attendance at an educational conference. 

  

	 	•	 	Offers and requests for funding for such scholarships should not come from or be directed to an Industry company’s marketing or sales departments. 

E. Unrestricted Grants 
 Unrestricted grants, (e.g.,
grants not provided for educational or other purposes described in this policy), could have the appearance of inappropriately attempting to influence USC Healthcare Professionals. USC Healthcare Professionals may not accept unrestricted grants.
Questions regarding unrestricted grants should be directed to the Office of Compliance. 
 F. Industry-sponsored Research Projects 

F.1 
 All Industry-sponsored research projects must be
reviewed and approved by USC’s Health Research Association or the USC Department of Contracts and Grants, and are subject to USC’s research policies generally; see Faculty Issues on USC Policies site, and in particular USC’s
Conflict of Interest in Research policy, a copy of which may be obtained at ooc.usc.edu/conflict-interest-research. 

F.2 
 Disclosures of potential or actual conflicts of
interest in research must be made to the relevant Institutional Review Board (IRB) and/or Conflicts of Interest Committee (CIRC) per the Conflict of Interest in Research policy and IRB procedures. 

F.3 
 The CIRC and IRB will consult with the Office of
Compliance and Department Chair as appropriate, in cases where this policy and the Conflict of Interest in Research policy both may apply to a particular disclosure. (There are circumstances where this policy and the Conflict of Interest in Research
policy may overlap but have different objectives. For example, a USC Healthcare Professional may be a Principal Investigator on an Industry-funded research project, but have a Consulting Arrangement that creates an actual or potential conflict of
interest as described under the Conflict of Interest in Research policy. The CIRC may review the Consulting Arrangement to confirm that it does not appear to bias the research design, protocol or outcomes. But the Consulting Arrangement also may
require review under Section A of this policy to ensure that it does not appear to influence particular prescribing or dispensing habits.) 
 G. Training
and Education Regarding Use of Medical Devices 
 G.1 

To ensure that USC Healthcare Professionals receive appropriate training free from inappropriate influences over their clinical decision-making, prescribing
and purchasing decisions, the following policies shall be followed regarding attendance at medical device manufacturer-sponsored training sessions: 

  
 7 

	 	•	 	USC Healthcare Professionals may attend educational training programs sponsored by manufacturers of clinical devices, so long as they are conducted in settings that are conducive to the effective transmission of
knowledge. Conducive settings are limited to facilities specifically designed to approximate the conditions of a surgical suite, or a working clinical laboratory or those designed to provide medical training on large and/or technical medical
devices, such as surgical equipment, implants, imaging and clinical laboratory equipment. Resort settings are not appropriate settings. USC Healthcare Professionals are discouraged from attending training sessions at international locations when a
US location is reasonably available. 

  

	 	•	 	USC Healthcare Professionals may accept reimbursement for reasonable travel, lodging and meals of modest value in connection with a training program meeting the criteria of Section G. See Exhibit C for guidelines on
what constitutes “modest value.” Any meals and receptions provided in connection with the training program should be subordinate in time and focus to the educational/training purpose(s) of the program. 

 

	 	•	 	Under no circumstances should USC Healthcare Professionals allow a medical device company to pay for meals, hospitality, travel or other expenses for their spouses or other guests who do not have a bona fide
professional interest in the information being provided at the training. 

 H. Pharmaceutical Samples, Discounts and Other Reductions in
Price 
 H.1 Use of Samples 
  

	 	•	 	It is permissible for USC Healthcare Professionals to utilize drug samples in the treatment of their patients, so long as the samples are not resold, billed for or used for an individual healthcare professional’s
personal benefit, and are distributed in accordance with this policy. However, USC Healthcare Professionals should never allow the provision of free drug samples to influence their clinical decision-making or purchasing decisions. 

H.2 Pharmaceutical Sample Distribution 
  

	 	•	 	Pharmaceutical samples may not be delivered to or dispensed from a practitioner’s office location. For clinics located outside of the USC Health Science Campus, special procedures for distribution must be developed
with and approved by the Office of Compliance. 

  

	 	•	 	Pharmaceutical samples must be delivered to a campus pharmacy for storage and dispensing. The dispensing of samples must comply with the provisions of USC Care Policy 135 entitled: Centralized Sample Management Program.

 H.3 Discounts 
 It is permissible for
USC Healthcare Professionals to accept discounts and other price reductions on goods or services only to the extent the discounts and price reductions comply with the federal Anti-Kickback laws and the following: 

 

	 	•	 	USC Healthcare Professionals may only accept a discount that is made at the time they purchase the goods or services or where the terms of any rebate are fixed and set forth in writing at the time of the initial sale of
a good or service. 

  

	 	•	 	USC Healthcare Professionals who have received a discount must ensure that any invoice, coupon or statement provided by Industry accurately reflects the discounted price. 

 

	 	•	 	USC Healthcare Professionals must retain documentation of any discount received from Industry for items or services billed to federal or state health care programs so that such documentation is readily accessible should
it be requested by a federal or state health agency. 

  
 8 

 H.4 
 Under
no circumstances may USC Healthcare Professionals charge a patient for a drug sample, or provide a drug sample to a patient, who is covered by a federal or state health care program where the cost of the drug is otherwise included within the payment
received from the federal or state health care program. 
 I. Site Access by Industry Representatives 

I.1 Registration 
 Industry representatives must be
registered in USC’s centralized Industry representative tracking system and comply with USC Care Medical Group Policy CL 135 entitled “Site Access by Pharmaceutical and Device Manufacturer Representatives.” As a part of this
registration process, representatives are required to: 
  

	 	•	 	Provide their name, contact information, immediate supervisor and the contact information for the Industry company’s Chief Compliance Officer; 

 

	 	•	 	Attest that they will abide by this policy; 

  

	 	•	 	Satisfy USC’s credentialing requirements as applicable. 

 I.2 Site Access/Pharmaceutical
Representatives 
 Site access by a registered Industry representative may occur only: 

 

	 	•	 	By appointment with a USC Healthcare Professional; 

  

	 	•	 	In non-patient care areas; 

  

	 	•	 	After obtaining security identification pass. Industry representatives may obtain a pass by checking in at one of the Industry representative kiosks which are located at both the Health Science Campus and University
Park Campus. 

 Representatives failing to obtain a security pass will be asked to leave the campus. 

I.3 Site Access/Device Representatives 
 It is understood
that site access by device manufacturers may be required for training or ongoing device refinement. Site access by a registered Industry representative in this case may occur only: 

 

	 	•	 	By appointment with a USC Healthcare Professional; 

  

	 	•	 	After obtaining a security identification pass; and 

  

	 	•	 	After the patient has signed USC’s applicable HIPAA authorization. 

 It is unacceptable for a device
representative to be in a patient-care area solely for marketing purposes and with the intent of influencing a USC Healthcare Professional’s treatment decisions. 

J. Ghostwriting 
 The AAMC defines ghostwriting as
“the provision of written material that is officially credited to someone other than the writer(s) of the material.” Transparent writing collaboration with attribution between academic and industry investigators, medical writers and/or
technical experts is not ghostwriting. It is not permissible for USC Healthcare Professionals, students or trainees to allow their professional presentations to be ghostwritten by any party. 

  
 9 

 K. Recusal from Purchasing Decisions 

Every employee of the university must avoid both actual conflicts of interest and the appearance of conflicts of interest and be in compliance with the
university’s Conflict of Interest and Ethics Policy and Procedures. 
 USC Healthcare Professionals are obligated to disclose to the appropriate
parties (e.g., Pharmacy and Therapeutics Committees, Chair/Supervisor), any past or current financial interests, management roles or consulting relationships with Industry which are relevant to the product/service under consideration. 

USC Healthcare Professionals must recuse themselves from any purchasing deliberations or decisions relevant to the conflicting interests that pertain to the
Industry’s products or services when there is an ongoing or current consulting relationship. 
 5. Enforcement 

The Office of Compliance in conjunction with various impacted units is available as a resource for the implementation and interpretation of this policy. All
USC Healthcare Professionals are encouraged to call the office should they need assistance or have questions about the policy. 
 5.1 Faculty and Staff

 Sanctions for violations of this policy for faculty will be in accordance with the Faculty Handbook. Sanctions for violations of this policy for staff
will be in accordance with the Staff Employment Policies and Procedures. Any disciplinary action against a faculty member or a staff employee under this policy should take into account the scale of the offense, the individual’s intent, and the
degree of wrongdoing. 
 5.2 Students 
 Sanctions for
violations of this policy for students will be in accordance with SCampus. 
 5.3 Industry 

Violation of this policy by Industry representatives will result in disciplinary action, including but not limited to the following: 

 

	 	•	 	Verbal and written warning to the representative and written notification to the representative’s supervisor. First violations will be documented in USC’s Site Access tracking system. 

 

	 	•	 	Suspension of the representative from campus. The representative’s supervisor must attest in writing that said representative has been counseled. 

 

	 	•	 	Suspension of the representative and all other company sales/marketing representatives from campus and any other interactions with faculty/staff on or off campus for a period of six months. 

Exhibit A: Summary of Applicable Law and Standards 
 It is
USC policy to ensure that all interactions with Industry are conducted in conformity with the federal Anti- Kickback laws, in addition to other applicable federal, state and local laws. Generally, the Anti-Kickback laws prohibit paying or receiving
anything of value, for which one purpose is to induce the receiver to use, recommend or purchase any products or services that may be paid for by Medicare, Medi-Cal or any other state or federal health care program. Violations of the law are
punishable by up to five years in prison, criminal fines up to $25,000, administrative civil money penalties up to $50,000, and exclusion from participation in federal health care programs. 

USC policy is informed by the voluntary guidelines developed by the American Medical Association (Ethical Opinion E-8.061), the Pharmaceutical Research and
Manufacturers of America “Code of Interactions with Health 

  
 10 

 
Care Professionals” (“PhRMA Code”), the Advanced Medical Technology Association’s “Code of Ethics on Interactions with Health Care Professionals” (“AdvaMed
Code”), the Office of the Inspector General’s (“OIG”) “Compliance Program Guidance for Pharmaceutical Manufacturers” (“OIG Compliance Guidance”) and the ACCME Standards for Commercial Support (“ACCME
Standards”). 
 In particular, USC seeks to comply with the general principles set forth in the OIG Compliance Guidance and to ensure that no
interactions with Industry have the potential to improperly influence clinical decision-making, inappropriately increase Medicare/Medicaid or other insurance costs, increase the risk of overutilization of health care services, or create patient
safety or quality of care concerns. 
 Shown below are links to the voluntary guidelines and government guidance noted above: American Medical Association
Ethical Opinion E-8.061 
 See www.ama-assn.org 
 PhRMA
Code 
 See www.phrma.org/files/PhRMA Marketing Code 2008.pdf 

AdvaMed Code 
 See
www.advamed.org/NR/rdonlyres/61D30455-F7E9-4081-B219- 12D6CE347585/0/AdvaMedCodeofEthicsRevisedandRestatedEffective20090701.pdf 
 OIG Compliance
Program Guidance for Pharmaceutical Manufacturers 
 See oig.hhs.gov/authorities/docs/03/050503FRCPGPharmac.pdf 

ACCME Standards for Commercial Support 
 See
www.accme.org/dir_docs/doc_upload/68b2902a-fb73-44d1-8725-80a1504e520c_uploaddocument.pdf 
 Medicare Anti-Kickback laws 

See www.law.cornell.edu/uscode/html/uscode42/usc_sec_42_00001320—a007b.html 

Exhibit B 
 The following are the USC affiliated faculty
practice plan corporations that are “Healthcare Professionals” under this policy (schools and departments that are not faculty practice plan corporations but who interact with Industry, including but not limited to, Dentistry, Pharmacy and
the Student Health Center, are subject to the same obligations as the faculty practice plan corporations under this policy): 
 USC Occupational Therapy
Associates, Inc. 
 USC Physical Therapy Associates, Inc. 
 USC
Care Medical Group, Inc. 
 Exhibit C: Specific Guidelines for establishing “Modest Value” in Meals, Travel and Lodging 

For USC-related activities, “Modest Value” is defined by the Expenditure Manual. Modest value means modest by local standards, but in no event may
exceed the following: (1) for out-of-town travel, the maximum value of meals, hospitality, travel (exclusive of plane fare) and lodging should not exceed the maximum rate of USC travel reimbursement for actual expenses, which is set each at a
maximum dollar value; and (2) if only certain individual items are provided, those items should not exceed the maximum allowed per item. 
 For non-USC
related activities, we recommend utilizing the USC definition of “modest value” along with the additional guidance provided below: 

  
 11 

	 	•	 	Lodging in Expensive Cities. For travel to more expensive cities (e.g., New York, Boston and certain foreign cities), the maximum lodging per night may exceed the USC maximum allowable. To select lodgings in such
cities that fall within the definition of modest value, utilize pricing guidance found in travel guides such as Fodors. For example, go to www.fodors.com. Click on the “hotels” tab and search for the city in question by price range. Do not
select a hotel found in the most expensive category but rather one that is listed at no more than $$$ by the Fodor scale. 

  

	 	•	 	Meals, Travel, Lodging and Other Incidentals beyond the Above Norms. Meals, hospitality, travel and lodging outside these norms would not be incidental to the work involved under the consulting or other service
contract. Such benefits are permitted only if treated as extra compensation that, combined with monetary compensation, is still fair market value for services provided by the USC Healthcare Professional. 

 

	 	•	 	Plane Fare. First-class or business-class tickets are generally prohibited except as otherwise permitted by USC policy. 

  

	 	•	 	Locations of Meetings. Meetings should take place at appropriate venues, such as conference hotels or other commercial meeting spaces, rather than at resorts. 

 

	 	•	 	Meals, Travel, Lodging must be Incidental. Meals, receptions and other hospitality are permitted so long as they constitute only an incidental part of any meetings for consulting services. For example, in
connection with an all-day meeting, a one-hour reception or meal would be acceptable. However, it would not be appropriate for an “all-day meeting” to consist of only three hours of lectures or meetings followed by an afternoon of golf or
other entertainment at a resort paid for by Industry. In this case, the hospitality provided to the USC Healthcare Professional would not be incidental to the work involved under the consulting or other service contract. Such benefits are permitted
only if treated as extra compensation that, combined with monetary compensation, is still fair market value for services provided by the USC Healthcare Professional. 

Responsible Office 
 Office of Compliance 

ooc.usc.edu 
 complian@usc.edu 

(213) 740-8258 
 Issued by 

Chrysostomos L. Nikias, Executive Vice President and Provost 

Todd R. Dickey, Senior Vice President, Administration 
 University
of Southern California 

  
 12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}]]